钙拮抗剂抗肝纤维化的实验与临床研究  

Experimental and clinical study of calcium channel blockers on antifibrosis in chronic liver diseases

作　　者：权启镇[1] 孙自勤[1] 李定国[2] 王要军[1] 车建途[2] 齐风[1] 范平[1] 

机构地区：[1]济南军区总医院,250031 [2]上海第二医科大学附属新华医院

出　　处：《世界华人消化杂志》1994年第4期214-217,197,共5页World Chinese Journal of Digestology

摘　　要：目的:研究钙通道阻滞刑(CCB)抗肝纤维化的作用。方法:应用CCB汉防己甲素(Tet).维拉帕米(Ver)对实验性肝纤维化大鼠及115例慢性肝病患者抗肝纤维化治疗,并临床随访36个月。结果:血清Ⅲ型前胶原肽(PⅢP)及血清透明质酸(HA)含量与治疗前相比明显降低(P<0.01);14例(15.4％)肝纤维化消失,54例(58.1％)胶原纤维沉积明显减轻,19例(20.4％)胶原纤维轻度减轻,炎性细胞浸润明显减轻或消失,储脂细胞(FSC)数量及内质网、线粒体平均面积均减少,总有效率为93.6％,与对照组相比有非常显著差异(P<0.01-0.001)。结论:CCB对肝纤维化有治疗作用。AIM To study the antifibrotic effect of calcium channel blockers)CCB)on chronic liver diseases.METHODS CCB,including tetrandrine)Tet)and verapine,were used to treat liver fibrosis in rats and in 115 patients withchronic liver diseases.The patients were followed up for 36 months.RESULTS Serum levels of typeⅢ procollagen peptide)pⅢp)and hyaluronic acid)HA)were significantly lower comparedto oretreatment)P<0.01).Liver fibrosis was completely disappeared in 14 patients)15.4%)and liver collagen depositionattenuated in 54 patients)58.1%).Inflammation in the liver was improved,and the number of fat-storing cells wasdecreased.The total effective rate was 93.6%.CONCLUSION CCB has definitely therapeutic effect on liver fibrosis.

关 键 词：钙拮抗剂 慢性肝病 肝纤维化 

分 类 号：R575.2[医药卫生—消化系统]